Drugmaker pulls 17K antifungal pills in Class I recall

In a Class I recall, the most serious type, a New Jersey drugmaker is removing 17,376 drug cartons from the market because of a cross-contamination risk. 

Scynexis is recalling two lots of Brexafemme (ibrexafungerp) tablets 150 milligram, 4 count cartons. The antifungal drug is approved for vulvovaginal candidiasis. 

The possible cross-contamination risk is with ezetimibe, a non-antibacterial beta-lactam compound that could lead to swelling, rash, hives, anaphylaxis and a life-threatening reaction, according to the FDA. No adverse events have been reported.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like